20^th Annual Pharma Middle East Congress November 11-12, 2019 Renaissance Polat Istanbul Hotel | Istanbul, Turkey

Biography:

Abstract:

Acne is a chronic inflammatory condition affecting people aged between 12-24 years. Causes of acne includes bacterial infection and hormonal changes. Treatment depends on the severity of acne Severe types of acne treated with isotretinoin

Objective: The purpose is to describe trends in the use of isotretinon for acne despite the side effects

Methods: Data from isotretinoin research studies and acne pathology studies

Results: Isotretinoin should only be used for very severe cases of acne which are not treated by other medications

Conclusion: Isotretinoin is assumed as a chemotherapy teratogenic treatment of acne. Most patients who receive oral isotretinoin will be free of acne by the end of 4–6 months of treatment depending on the dose administered. At the same time they have to be aware of side effects that may be long term side effects and irreversible.

Biography:

Yavuz Selim Silay is the Co-Founder & CEO of MaQasid Angel Investors Network (MAIN) and Chairman of Istanbul Consulting Group. He is currently the Co-Founder of BioCube Istanbul Bioentrepreneurship & Innovation Center and Corporate Communication Director of Archem Diagnostics. He previously managed the largest distributor of Siemens Healthcare in Turkey managing 250 employees and Director of Avcılar Hospital R&D Center. Previously he has worked as the Market Access & Health Policy Director for AIFD in Turkey. He has previously worked as the Vice President of Ipsen Pharmaceutical and Director of Teva Pharmaceutical in USA managing large clinical trials as well as Investigator initiated trials and developing relationships with key opinion leaders. He was the Associate Director at KV Pharmaceuticals and Director in Clinical Development Department at Forest Laboratories. He has earned his MD from the Faculty of Medicine, University of Ankara in Ankara, Turkey. He has completed a Clinical Internship at Baylor College of Medicine in Houston, followed by continued research training at The University of Texas MD Anderson Cancer Center in Houston. He recently completed his Executive MBA at the Olin Business School at Washington University in St. Louis

Abstract:

Pharmaceutical, biotech and medical device companies are constantly evaluating how decisions at the US, Europe, Turkey and emerging markets are taken at the federal and state level and how it will impact provider and patient access and coverage to their therapies. To gain these critical insights, government affairs & medical affairs teams require speaking with those on the frontlines of healthcare delivery: Physicians, allied healthcare professionals, payers and patients. New generation government engagement and commercial diplomacy approach developed by Istanbul Consulting Group (ICG) will be provided with unique cases. Dr. Yavuz Selim Silay a global leader and seasoned expert in Government engagement, Commercial Diplomacy, Corporate Communications, Government affairs & Medical Affairs will discuss how companies utilizing Government Affairs and Medical affairs teams should engage decision makers, payers, physicians and acquire these insights in a convenient, cost-effective and compliant manner in this current changing global regulatory landscape..

Biography:

Yasir Karkar has completed his BSc in Pharmacy from Al-Mustansiryia University, Iraq in 2012 and worked for four years as Pharmacist in Ministry of Health in Iraq. He did his MSc in Pharmaceutical Technology at the University of Bradford. He is presently working as an Assistant Lecturer in Al-Ayen University since 2018.

Abstract:

Cocrystals are multicomponent supramolecular solid forms in which the components are present in stoichiometric ratio. The components that are solid at ambient condition are held together by hydrogen bonds rather than ionic bond which set them apart from salts. Although the first cocrystal dates back to 1844, cocrystallization is only regained interest in the last decade because of their ability to fine-tune the solubility, dissolution rate and other physicochemical properties without altering the chemical structure of the molecule. The aim of this study was to utilize the principles of crystal engineering to improve the physiochemical properties of proton pump inhibitors. Omeprazole was chosen as the subject of this study because it is the first synthesized molecule among proton pump inhibitors and it is to date a blockbuster drug. Before screening attempts, molecular modelling was used to predict cocrystallization possibility and we were able to shortlist the coformers from 9 to 5 potential coformers. Thereafter, we were able to cocrystallize omeprazole with caffeine using liquid assisted grinding in a ball mill. This cocrystal was investigated using thermal analysis, PXRD and FT-IR because single crystal suitable for single crystal X-ray diffraction structure study could not be obtained. Further characterization of this cocrystal indicate it has advantage over omeprazole in terms of solubility, dissolution rate, hygroscopicity and photostability, but offer no advantage in acid stability in solution, however, further testing of the stability with acidic coat need to be carried out

Biography:

Alaa El Kazak, studied pharmaceutical sciences at the faculty of Pharmacy, Alexandria University and proceeded to work in a fast-growing national company in the R&D department. Passionate about pharmaceutical research, he earned his master’s degree in pharmaceutics, where he developed sophisticated oral delivery system utilizing advanced experimental designs. In 2012, with encouragement from his managers, he was involved in pharmaceutical regulatory affairs until he headed the registration unit in the company. In mid-2013, he moved to KSA to lead the R&D department in a national Saudi company, where he established the R&D department and planned the expansion of the company products profile. Challenging his experience and seeking for deeper exposure in regulatory affairs field, he joined an international Saudi-Japanese venture company where he is exposed to broad activities in product lifecycle management of brand and generic products on the national and the regional levels.

Abstract:

The cost of prescription drugs has been overwhelming different healthcare systems all over the world, especially with the emergence of specialty drugs. The introduction of lower price generic products is encouraged by national jurisdictions as a cost-containment measure against the highly priced off-patent branded products. The dramatic sales losses of brand products due to patent expiry have driven Big Pharma companies to embrace “evergreening” strategies to oppose the effect of genericization. Evergreening aims at maximizing the profits of existing near-to-expire patents, especially with the increased R&D costs and the diminished ability of developing new blockbuster medicines. Tactics used by originators to extend patents may include obtaining secondary patents for new molecular structures, methods of manufacturing, crystalline forms, formulas, dosage forms, combinations and/or indications. Such tactics have been proved to be efficient in stabilizing the originator market share and mitigating both generics introduction effect and jurisdictions cost-containment policies. Accordingly, authorities should set rational measures to detect and prevent patent abuse; to guarantee patients accessibility to affordable drugs and to reduce the global health care burden without compromising the innovation continuity.

Biography:

Abstract:

Respiratory complex I (NADH- ubiquinone Oxidoreductase) is the largest protein complex of the respiratory chains that catalyzes the transfer of electrons from NADH to coenzyme Q10 (CoQ10). Dysfunction of this protein complex can cause many hereditary and degenerative diseases. Notwithstanding many types of research, the mechanism of action of this complex is not entirely understood. Hence, increasing number of inhibitors of mammalian Complex I may bring about clues to the enzyme mechanism. In this study, a virtual screening method combined with pharmacophore modeling was utilized to search and identify new potential natural compounds acting on inhibition of mitochondrial complex I. To this aim, a 3D QSAR model was made and validated to be utilized in virtual screening in-order to identify a new scaffold. Then the lead compounds were subsequently subjected to molecular docking studies for their binding to the X-ray structure of the biological target. Two different types of crystal structure of the target-structure of membrane arm and structure of membrane and peripheral arm-were selected to investigate the Interface between peripheral and membrane arm as well as ubiquinone access. For all molecular modeling, the small-Molecular Drug Discovery Suite 2015-2(Schrodinger, LLC, New York, NY, 2016) was used. DQA, 2-decyl-4-quinazolinylamine, was included as a positive control in this study. As result, several compounds showed good binding affinity to the targets and finally 10 compounds with the highest binding affinities, much more than DQA, were selected as potent compounds. Based on computed docking score these compounds, with the docking score range of -7.9 – -10.85 KJ/mol, have a high tendency to inhibit complex I. Also, all Inhibitors acted on the ubiquinone reduction site of this complex. It is hoped these compounds can be good candidates in the focus of biomedical researches, and their backbone structural scaffold can present as building blocks in designing drug-like molecules for respiratory complex I.